ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately.
Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet’s Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the right time to implement this leadership transition. Mr. Hollingshead has entered into a consulting arrangement with the Company to facilitate a smooth transition.
“Insulet continues to successfully deliver on its financial, clinical, and operational objectives while advancing its mission to improve the lives of people with diabetes, and we are confident this leadership change will further the Company’s success,” said Timothy Scannell, Chairman of Insulet’s Board of Directors. “Having stepped into the CEO role from the Board of Directors, Jim has led Insulet through a very strong period of growth and development. During Jim’s tenure, Insulet launched its flagship product, Omnipod 5, which has achieved clear market leadership in type 1 diabetes in the U.S. and Europe, and was the first to market in Automated Insulin Delivery for type 2 diabetes in the U.S. As Jim hands over the reins, Insulet is the clear global leader in our market, and poised to grow and scale even further. We’re grateful for his contributions, and we wish him the best in his future endeavors.”
Mr. Scannell continued, “Our Board conducted a thorough search to identify a dynamic executive with a sophisticated understanding of the MedTech market and a passion for improving lives. In Ashley, we found not only a world-class leader with nearly three decades of healthcare leadership experience, but a visionary with unique insight into operating at the intersection of MedTech and Consumer Health. She brings a track record of driving growth and innovation through market and category creation, including as Executive Vice President and Worldwide Chairman of Johnson & Johnson’s MedTech business, and has deep diabetes experience, having previously served as Group Chairman of Johnson & Johnson Vision and Diabetes Care. We believe that, under Ashley’s leadership, Insulet will achieve even greater success, strengthen growth and innovation, and deliver superior returns for investors.”
“Insulet has transformed diabetes care, and I am honored to join the Company as its next CEO,” said Ms. McEvoy. “Insulet has massive, untapped growth potential, a talented team, unparalleled pharmacy channel access and manufacturing capabilities, and deeply loyal customers – remarkable differentiators and a strong foundation for continued success. At this critical moment in the Company and market’s evolution, Insulet has a unique opportunity to enhance innovation, drive global expansion, and win the hearts and minds of more providers and consumers by thinking differently about the experiences and needs of people with diabetes. I am excited to work alongside Insulet’s accomplished team to do just that – and in the process, continue to revolutionize diabetes care and make life easier for people living with diabetes, while driving value creation for shareholders.”
“It has been a privilege to serve as Insulet’s CEO,” said Mr. Hollingshead. “I am immensely proud of what our team has accomplished in redefining diabetes care through the simplicity and sophistication of the Omnipod platform. I will be forever grateful to all of my colleagues at Insulet for their passion and dedication for improving and simplifying lives for people living with diabetes, which has led us to tremendous success, and more importantly helped us to reach hundreds of thousands of customers all over the world. I look forward to seeing all that will be achieved going forward.”
2025 Outlook
Insulet expects to exceed its previously provided first quarter revenue guidance and intends to raise guidance for the full year.
The Company will provide further details on its first quarter 2025 earnings call on May 8, 2025, after the close of the financial markets.
2025 Investor Day
In light of the CEO transition, Insulet has postponed its planned Investor Day, which was previously scheduled for June 5, 2025. The Company intends to reschedule the Investor Day to a later date.
About Ashley McEvoy
Ashley McEvoy is an experienced healthcare executive and Board member. From 1996 to 2023, she served in leadership roles of increasing responsibility at Johnson & Johnson, most recently as Executive Vice President and Worldwide Chairman of Johnson & Johnson’s MedTech business, an organization with 60,000 global employees and revenue of more than $30 billion. In that role, she accelerated revenue growth while expanding the business’s presence in higher growth markets and doubling the value of the business’s new product pipeline. Earlier in her tenure at Johnson & Johnson, she served as Company Group Chairman of Vision and Diabetes Care for six years, Worldwide President of Ethicon Inc. for three years, and President of McNeil Consumer Healthcare for three years, among other leadership roles. Since 2023, Ms. McEvoy has been a member of the Procter & Gamble Board of Directors, serving on the Compensation & Leadership Development and Innovation & Technology Committees. She previously served on the Board of Trustees for the Children’s Hospital of Philadelphia.
Ms. McEvoy has been named to FORTUNE’s “Future Fortune 500 CEOs” list and Forbes’ inaugural “CEO Next” list. In 2019, she was named to FORTUNE’s “Most Powerful Women” list, and she was also recognized as a Woman of Achievement by the National Association of Female Executives the following year. She also ranked #1 on The Healthcare Technology Report’s “Top 25 Women Leaders in Medical Devices” list in 2021.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit Insulet.com or omnipod.com.
